Prognostic Value of Circulating MicroRNA-210 Levels in Patients with Moderate to Severe Aortic Stenosis
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Circulating micro-RNAs have been proposed as a novel class of cardiovascular (CV) biomarkers, but whether they meet analytical requirements and provide additional information to establish risk indices have not been established. miR-210 levels are increased in subjects with low VO2 max, which is a recognized risk factor in patients with aortic stenosis (AS), and we hypothesized that circulating miR-210 levels may be increased in patients with AS and associated with a poor prognosis. METHODS: We measured circulating miR-210 levels by real-time PCR in 57 patients with moderate to severe AS and in 10 age- and gender-matched healthy controls. The merit of miR-210 as a biomarker was assessed according to established criteria, including by comparing miR-210 levels with NT-proBNP and miR-22 levels, which is another miRNA biomarker candidate. RESULTS: All patients and control subjects had miR-210 levels within the range of detection (Cq<35) and the analytical variability was low. Circulating miR-210 levels were 2.0±0.2 [mean±SEM] fold increased in AS patients compared to controls (p = 0.002), whereas miR-22 levels were not differently expressed in the AS patients (0.12±0.06 fold increase, p = 0.45). The increase in miR-210 levels in AS patients was comparable to the increment in NT-proBNP levels: [AUC] 0.82 (95% CI 0.70-0.90) vs. 0.85 (0.75-0.93), respectively, p = 0.71. During a median follow-up of 1287 days, 15 patients (26%) died. There was a significant association between higher circulating levels of miR-210 and increased mortality during follow-up: hazard ratio [supra- vs. inframedian levels] 3.3 (95% CI 1.1-10.5), p = 0.039. Adjusting for other risk indices in multivariate analysis did not attenuate the prognostic merit of circulating miR-210 levels. CONCLUSION: Circulating miR-210 levels are increased in patients with AS and provide independent prognostic information to established risk indices. Analytical characteristics were also excellent supporting the potential of micro-RNAs as novel CV biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Extraction from serum and RT-qPCR of the spike-in control cel-miR-39 were performed with minimal variation between samples (CV 2.4% for AS patients [#1–36 and #38–58] and 2.2% for the control subjects [#59–74]), which indicates that miRNAs seem to meet the analytical requirements proposed for novel biomarkers. Data are presented as the absolute Cq values.](https://figures.cochat.ai/paper-figures/678847b274d646b69214505dfab52b51/prognostic-value-of-circulating-microrna-210-levels-in-patients-with-moderate-to-figure-1.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“but their incremental value beyond already established clinical, echocardiographic, tomographic and blood biomarkers is yet to be demonstrated.”
From Calcific aortic stenosis (2016) · cites this paper as [197]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging blood biomarkers, such high-sensitivity cardiac troponin194;195, growth/differentiation factor 15, soluble interleukin-1 receptor-like 1 (also called protein ST2) and micro RNAs196–198, might be helpful to detect subclinical and/or irreversible myocardial dysfunction”
From Calcific aortic stenosis (2016) · cites this paper as [197]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., et al. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2005.10.005 · Cited by 11,318 · cited 1×
“LV dimension, septal and posterior wall thickness, and mass were measured as recommended [30].”
MethodArroyo, J. D., Chevillet, J. R., Kroh, E. M., Ruf, I. K., Pritchard, C. C., Gibson, D. F., Mitchell, P. S., Bennett, C. F., Pogosova-Agadjanyan, E. L., Stirewalt, D. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019055108 · Cited by 3,294 · cited 1×
“Moreover, the release of miRNAs to the circulation and the transport of miRNAs throughout the body bound to proteins [4], lipids [5], or as part of microvesicles [4] suggest that miRNAs may represent a new class of cardiovascular (CV) biomarkers [6].”
BackgroundMicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., & Remaley, A. T. (2011) · Nature Cell Biology · doi:10.1038/ncb2210 · Cited by 2,741 · cited 1×
“Moreover, the release of miRNAs to the circulation and the transport of miRNAs throughout the body bound to proteins [4], lipids [5], or as part of microvesicles [4] suggest that miRNAs may represent a new class of cardiovascular (CV) biomarkers [6].”
BackgroundPlasma MicroRNA Profiling Reveals Loss of Endothelial MiR-126 and Other MicroRNAs in Type 2 Diabetes
Zampetaki, A., Kiechl, S., Drozdov, I., Willeit, P., Mayr, U., Prokopi, M., Mayr, A., Weger, S., Oberhollenzer, F., Bonora, E., et al. (2010) · Circulation Research · doi:10.1161/circresaha.110.226357 · Cited by 1,283 · cited 3×
“miRNAs also cluster in networks based on common physiological properties and most previous miRNA biomarker studies have explored several miRNAs in combination [8,9].”
BackgroundMethodPervasive roles of microRNAs in cardiovascular biology
Small, E. M., & Olson, E. N. (2011) · Nature · doi:10.1038/nature09783 · Cited by 1,180
Hlatky, M. A., Greenland, P., Arnett, D. K., Ballantyne, C. M., Criqui, M. H., Elkind, M. S. V., Go, A. S., Harrell, F. E., Hong, Y., Howard, B. V., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192278 · Cited by 1,139 · cited 1×
“However, from a statistical point of view the substantial event rate (26% mortality) during follow-up is considered of more importance than the absolute number of patients included in the study [28].”
BackgroundMicroRNAs in the Human Heart: A Clue to Fetal Gene Reprogramming in Heart Failure
Thum, T., Galuppo, P., Wolf, C., Fiedler, J., Kneitz, S., van Laake, L. W., Doevendans, P. A., Mummery, C. L., Borlak, J., Haverich, A., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.687947 · Cited by 888
Circulating microRNAs are new and sensitive biomarkers of myocardial infarction
D'Alessandra, Y., Devanna, P., Limana, F., Straino, S., Di Carlo, A., Brambilla, P. G., Rubino, M., Carena, M. C., Spazzafumo, L., De Simone, M., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq167 · Cited by 797 · cited 1×
“Circulating miR-210 levels have also been found elevated in patients with myocardial infarction [22] and peripheral artery disease [23], and to provide prognostic information independently of established risk indices in patients with acute kidney injury [24].”
BackgroundBenchmarks for the Assessment of Novel Cardiovascular Biomarkers
Morrow, D. A., & de Lemos, J. A. (2007) · Circulation · doi:10.1161/circulationaha.106.683110 · Cited by 561 · cited 5×
“To the best of our knowledge, our study is the first to examine miRNA biomarkers in a stringent manner according to the criteria proposed by Morrow and de Lemos [7].”
BackgroundMethodInfluentialOtto, C. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.002 · Cited by 499 · cited 1×
“The close association between circulating miR-210 levels and aerobic fitness suggest that miR-210 may have merit as a prognostic biomarker in patients with cardiovascular disease (CVD) and especially in patients with aortic stenosis (AS) as aerobic capacity is an important risk factor and used for selection to surgery…”
BackgroundProspective Study on Circulating MicroRNAs and Risk of Myocardial Infarction
Zampetaki, A., Willeit, P., Tilling, L., Drozdov, I., Prokopi, M., Renard, J.-M., Mayr, A., Weger, S., Schett, G., Shah, A., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.056 · Cited by 464 · cited 1×
“miRNAs also cluster in networks based on common physiological properties and most previous miRNA biomarker studies have explored several miRNAs in combination [8,9].”
BackgroundCirculating microRNAs as novel biomarkers for platelet activation.
Willeit, P., Zampetaki, A., Dudek, K., Kaudewitz, D., King, A., Kirkby, N. S., Crosby-Nwaobi, R., Prokopi, M., Drozdov, I., Langley, S. R., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300539 · Cited by 365 · cited 1×
“In contrast, platelets do not seem to be an important contributor to miR-210 levels [19].”
BackgroundMicroRNA-210: A unique and pleiotropic hypoxamir
Chan, S. Y., & Loscalzo, J. (2010) · Cell Cycle · doi:10.4161/cc.9.6.11006 · Cited by 357 · cited 2×
“An interesting miRNA biomarker candidate is miR210 as miR-210 production is closely linked to cellular hypoxia [10].”
BackgroundProfiling of circulating microRNAs: from single biomarkers to re-wired networks
Zampetaki, A., Willeit, P., Drozdov, I., Kiechl, S., & Mayr, M. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvr266 · Cited by 258
Chang, K. H., Mestdagh, P., Vandesompele, J., Kerin, M. J., & Miller, N. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-173 · Cited by 225 · cited 2×
“We normalized miR-210 levels to miR-425 levels as miR-425 recently was reported as a circulating miRNA for normalization [17] and we have found miR-425 to be expressed closest to the geomean in two screening studies exploring 720 miRNAs in total (n = 34) (Figure S1 demonstrating r = 0.”
BackgroundIdentification of miR-130a, miR-27b and miR-210 as serum biomarkers for atherosclerosis obliterans
Li, T., Cao, H., Zhuang, J., Wan, J., Guan, M., Yu, B., Li, X., & Zhang, W. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.09.029 · Cited by 213 · cited 1×
“Circulating miR-210 levels have also been found elevated in patients with myocardial infarction [22] and peripheral artery disease [23], and to provide prognostic information independently of established risk indices in patients with acute kidney injury [24].”
BackgroundCirculating miR-210 Predicts Survival in Critically Ill Patients with Acute Kidney Injury
Lorenzen, J. M., Kielstein, J. T., Hafer, C., Gupta, S. K., Kümpers, P., Faulhaber-Walter, R., Haller, H., Fliser, D., & Thum, T. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00430111 · Cited by 204 · cited 1×
“Circulating miR-210 levels have also been found elevated in patients with myocardial infarction [22] and peripheral artery disease [23], and to provide prognostic information independently of established risk indices in patients with acute kidney injury [24].”
BackgroundCirculating MicroRNAs and Aerobic Fitness – The HUNT-Study
Bye, A., Røsjø, H., Aspenes, S. T., Condorelli, G., Omland, T., & Wisløff, U. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057496 · Cited by 165 · cited 3×
“Analogous to our previous publication on circulating miRNAs and physical capacity [11], we normalized miR-210 levels against miR-425 levels.”
BackgroundResultInfluentialSelf-citationRisk stratification of patients with aortic stenosis
Vahanian, A., & Otto, C. M. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp575 · Cited by 148 · cited 2×
“Current risk stratification in patients with aortic stenosis (AS) is based on symptoms (dyspnea, syncope, chest pain) and the identification of aortic valve orifice narrowing by echocardiography [1].”
BackgroundLeft Ventricular Subendocardial Ischemia in Severe Valvar and Supravalvar Aortic Stenosis
Vincent, W. R., Buckberg, G. D., & Hoffman, J. I. E. (1974) · Circulation · doi:10.1161/01.cir.49.2.326 · Cited by 130
Analytical challenges and technical limitations in assessing circulating MiRNAs
Mayr, M., & Zampetaki, A. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-02-0097 · Cited by 125 · cited 1×
“Leading researchers in the field also advocate a combination of a spike-in control to assess extraction quality and the use of a stable miRNA for normalization [15,16].”
BackgroundMicroRNA 210 as a Biomarker for Congestive Heart Failure
Endo, K., Naito, Y., Ji, X., Nakanishi, M., Noguchi, T., Goto, Y., Nonogi, H., Ma, X., Weng, H., Hirokawa, G., et al. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00578 · Cited by 115 · cited 2×
“Other groups have also found circulating miR-210 levels linked to CVD as miR-210 levels are increased in proportion to the severity of heart failure [20,21].”
BackgroundHypoxia-inducible Factor 1-α Induces miR-210 in Normoxic Differentiating Myoblasts
Cicchillitti, L., Stefano, V. D., Isaia, E., Crimaldi, L., Fasanaro, P., Ambrosino, V., Antonini, A., Capogrossi, M. C., Gaetano, C., Piaggio, G., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.421255 · Cited by 102 · cited 1×
“This model needs to be further explored in additional clinical and experimental studies, but is supported by previous experimental investigations demonstrating hypoxia inducible factor-1a regulated miR-210 expression during cellular hypoxia [26].”
ResultKaudewitz, D., Lee, R., Willeit, P., McGregor, R., Markus, H. S., Kiechl, S. J., Zampetaki, A., Storey, R. F., Channon, K. M., & Mayr, M. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-05-0368 · Cited by 98 · cited 2×
“CelmiR-39 has also been demonstrated to differ according to medication [14], which reduces the quality of cel-miR-39 as the normalization strategy.”
BackgroundResultRøsjø, H., Andreassen, J., Edvardsen, T., & Omland, T. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.02.346 · Cited by 83 · cited 1×
“Information regarding medical history, current symptoms, medication, and functional class was obtained from the medical records, as previously reported [29].”
MethodSelf-citationOmland, T. (2008) · Critical Care Medicine · doi:10.1097/01.ccm.0000296266.74913.85 · Cited by 80 · cited 6×
“The close association between circulating miR-210 levels and aerobic fitness suggest that miR-210 may have merit as a prognostic biomarker in patients with cardiovascular disease (CVD) and especially in patients with aortic stenosis (AS) as aerobic capacity is an important risk factor and used for selection to surgery…”
InfluentialSelf-citationRøsjø, H. R., Kravdal, G., Høiseth, A. D., Jørgensen, M. E., Badr, P., Røysland, R., & Omland, T. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.190868 · Cited by 64 · cited 1×
“2%, respectively, are well within the range that we also see for commercially available protein assays, including previously reported coefficient of variations for two high-sensitivity troponin assays in our laboratory [13].”
BackgroundSelf-citationZhao, D.-S., Chen, Y., Jiang, H., Lu, J., Zhang, G., Geng, J., Zhang, Q. H., Shen, J.-H., Xin Min, Z. H. O. U., Zhu, W., et al. (2013) · Cardiovascular Pathology · doi:10.1016/j.carpath.2013.04.001 · Cited by 59 · cited 1×
“Other groups have also found circulating miR-210 levels linked to CVD as miR-210 levels are increased in proportion to the severity of heart failure [20,21].”
BackgroundCirculating MicroRNAs in Cardiovascular Disease
McManus, D. D., & Ambros, V. (2011) · Circulation · doi:10.1161/circulationaha.111.062117 · Cited by 52 · cited 1×
“Moreover, the release of miRNAs to the circulation and the transport of miRNAs throughout the body bound to proteins [4], lipids [5], or as part of microvesicles [4] suggest that miRNAs may represent a new class of cardiovascular (CV) biomarkers [6].”
BackgroundPredicting Outcome in Patients With Asymptomatic Aortic Stenosis
Coglianese, E. E., & Davidoff, R. (2009) · Circulation · doi:10.1161/circulationaha.109.875591 · Cited by 14 · cited 1×
“Hence, irreversible myocardial damage may occur before the patients experience symptoms, and additional means to identify high-risk patients are needed [2].”
Background
Cited by
Lindman, B. R., Clavel, M.-A., Mathieu, P., Iung, B., Lancellotti, P., Otto, C. M., & Pibarot, P. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.6 · Cited by 982
MicroRNA and Cardiovascular Diseases
Çakmak, H. A., & Demir, M. (2020) · Balkan Medical Journal · doi:10.4274/balkanmedj.galenos.2020.2020.1.94 · Cited by 160
“Moreover, miR-210, miR-21, and miR-133a, which play a key role in left ventricular remodeling and fibrosis, were reported as strong prognostic biomarkers in patients with aortic stenosis in the literature (72-74,75).”
BackgroundMicroRNAs as Important Regulators of Exercise Adaptation
Silva, G. J. J., Bye, A., el Azzouzi, H., & Wisløff, U. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.06.003 · Cited by 155
Self-citationBye, A., Røsjø, H. R., Nauman, J., da Silva, G. J. J., Follestad, T., Omland, T., & Wisløff, U. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.05.009 · Cited by 142
“miR-425-5p has previously been found to be a stable expressed miR in other cohorts [36, 37].”
BackgroundMethodSelf-citationMolecular insights of exercise therapy in disease prevention and treatment
Walzik, D., Chirino, T. Y. W., Zimmer, P., & Joisten, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01841-0 · Cited by 106
“69 Other miRNAs such as miR-106a-5p, miR-424-5p, let-7g-5p, miR-144-3p and miR-660-5p were shown to predict future risk of fatal acute myocardial infarction in healthy individuals.”
Background
Metadata
- Authors
- Røsjø, H., Dahl, M. B., Bye, A., Andreassen, J., Jørgensen, M., Wisløff, U., Christensen, G., Edvardsen, T., & Omland, T.
- Affiliations
- University of Oslo (NO)
- Norwegian University of Science and Technology (NO)
- Oslo University Hospital (NO)
- Corresponding author
- Røsjø, Helge
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-03-13
- Volume
- 9
- Issue
- 3
- Pages
- e91812
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3953554
- OpenAlex
- W2000385072
- Cited by
- 41
- References
- 32
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 5 · 2020: 6 · 2019: 6 · 2018: 2 · 2017: 5 · 2016: 5 · 2015: 2
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- BIBSYS Brage (BIBSYS (Norway)) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
- Funders
- Universitetet i Oslo
- Akershus Universitetssykehus
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- aortic stenosis, circulating microRNAs, miR-210, miR-22, NT-proBNP, prognostic factors, mortality prediction, cardiovascular risk stratification, analytical variability, risk index, follow-up mortality, heart failure risk, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction
- MeSH terms
- Adult, Aged, Aortic Valve Stenosis, Female, Humans, Male, Prognosis, Risk Factors, Biomarkers, MicroRNAs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.